| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 21 | 2024 | 1676 | 1.390 |
Why?
|
| Immunotherapy, Adoptive | 14 | 2024 | 801 | 1.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2023 | 1197 | 0.760 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2020 | 477 | 0.530 |
Why?
|
| Genetic Therapy | 7 | 2024 | 673 | 0.470 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2024 | 157 | 0.450 |
Why?
|
| Graft vs Host Disease | 6 | 2022 | 542 | 0.440 |
Why?
|
| Receptor, ErbB-2 | 4 | 2024 | 493 | 0.440 |
Why?
|
| Hodgkin Disease | 4 | 2020 | 293 | 0.440 |
Why?
|
| Oncolytic Viruses | 2 | 2024 | 71 | 0.420 |
Why?
|
| Tissue and Organ Procurement | 1 | 2015 | 218 | 0.410 |
Why?
|
| Lymphoma | 3 | 2023 | 322 | 0.400 |
Why?
|
| Herpesvirus 4, Human | 7 | 2018 | 659 | 0.400 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 64 | 0.370 |
Why?
|
| Stem Cells | 1 | 2015 | 700 | 0.360 |
Why?
|
| Antigens, CD19 | 5 | 2024 | 177 | 0.350 |
Why?
|
| Salvage Therapy | 3 | 2021 | 193 | 0.340 |
Why?
|
| Caspase 9 | 3 | 2015 | 75 | 0.330 |
Why?
|
| Ki-1 Antigen | 2 | 2020 | 27 | 0.320 |
Why?
|
| Neuroblastoma | 4 | 2023 | 509 | 0.320 |
Why?
|
| Drugs, Investigational | 2 | 2023 | 22 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 1115 | 0.310 |
Why?
|
| Sarcoma | 2 | 2024 | 194 | 0.300 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 162 | 0.280 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2016 | 183 | 0.270 |
Why?
|
| Retroviridae | 4 | 2022 | 194 | 0.270 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2013 | 501 | 0.260 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 286 | 0.240 |
Why?
|
| Neoplasms | 3 | 2024 | 2772 | 0.240 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.230 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 388 | 0.230 |
Why?
|
| Interleukin-15 | 1 | 2024 | 91 | 0.230 |
Why?
|
| Leukemia | 3 | 2022 | 376 | 0.230 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 135 | 0.220 |
Why?
|
| Marketing | 1 | 2023 | 8 | 0.220 |
Why?
|
| Gangliosides | 1 | 2024 | 64 | 0.220 |
Why?
|
| Neomycin | 2 | 2000 | 36 | 0.220 |
Why?
|
| Compassionate Use Trials | 1 | 2023 | 14 | 0.220 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 285 | 0.210 |
Why?
|
| Interleukin-2 | 4 | 2005 | 229 | 0.210 |
Why?
|
| Natural Killer T-Cells | 1 | 2023 | 77 | 0.200 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 228 | 0.200 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 83 | 0.200 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 659 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 137 | 0.200 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 194 | 0.190 |
Why?
|
| Humans | 41 | 2024 | 123184 | 0.190 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 30 | 0.190 |
Why?
|
| Lymphocyte Transfusion | 1 | 2021 | 57 | 0.180 |
Why?
|
| Recurrence | 7 | 2022 | 1422 | 0.180 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.180 |
Why?
|
| Immunotherapy | 4 | 2023 | 653 | 0.170 |
Why?
|
| Anemia | 1 | 2024 | 339 | 0.170 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 45 | 0.170 |
Why?
|
| Virus Replication | 1 | 2022 | 603 | 0.160 |
Why?
|
| Child | 16 | 2024 | 24244 | 0.160 |
Why?
|
| Male | 26 | 2024 | 60083 | 0.160 |
Why?
|
| Cancer Vaccines | 3 | 2005 | 186 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 169 | 0.150 |
Why?
|
| Adenoviridae | 5 | 2023 | 605 | 0.150 |
Why?
|
| Adult | 16 | 2024 | 29065 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 673 | 0.150 |
Why?
|
| Treatment Outcome | 13 | 2024 | 12129 | 0.150 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.140 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 200 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 577 | 0.140 |
Why?
|
| DNA Viruses | 1 | 2017 | 33 | 0.140 |
Why?
|
| Female | 25 | 2024 | 65494 | 0.140 |
Why?
|
| Young Adult | 9 | 2024 | 8885 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 992 | 0.140 |
Why?
|
| Middle Aged | 14 | 2024 | 26002 | 0.140 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 123 | 0.130 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 31 | 0.130 |
Why?
|
| Adolescent | 14 | 2024 | 19118 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 105 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 99 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2000 | 714 | 0.130 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 1240 | 0.130 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2015 | 49 | 0.130 |
Why?
|
| CD28 Antigens | 2 | 2017 | 78 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 766 | 0.130 |
Why?
|
| CD40 Ligand | 2 | 2005 | 64 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 532 | 0.120 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 239 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2017 | 333 | 0.110 |
Why?
|
| Aged | 9 | 2024 | 19088 | 0.110 |
Why?
|
| Cytokines | 4 | 2024 | 1283 | 0.110 |
Why?
|
| United States Food and Drug Administration | 2 | 2024 | 148 | 0.100 |
Why?
|
| Transgenes | 1 | 2014 | 334 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 70 | 0.100 |
Why?
|
| Vidarabine | 2 | 2024 | 79 | 0.100 |
Why?
|
| Immunophenotyping | 4 | 2017 | 330 | 0.100 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 1991 | 20 | 0.100 |
Why?
|
| Chemokines, C | 2 | 2002 | 10 | 0.100 |
Why?
|
| Sialoglycoproteins | 2 | 2002 | 48 | 0.100 |
Why?
|
| Lymphokines | 2 | 2002 | 66 | 0.100 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2011 | 66 | 0.090 |
Why?
|
| Transplantation, Autologous | 3 | 2020 | 296 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 217 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1231 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 517 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 427 | 0.090 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 420 | 0.090 |
Why?
|
| Genetic Vectors | 3 | 2022 | 934 | 0.090 |
Why?
|
| Remission Induction | 3 | 2020 | 300 | 0.090 |
Why?
|
| Imidazoles | 1 | 1991 | 199 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 531 | 0.080 |
Why?
|
| Organic Chemicals | 3 | 2015 | 59 | 0.080 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 268 | 0.080 |
Why?
|
| Child, Preschool | 8 | 2024 | 13889 | 0.080 |
Why?
|
| Gene Transfer Techniques | 3 | 2011 | 355 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 1217 | 0.080 |
Why?
|
| Cell Line | 3 | 2022 | 2772 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2016 | 753 | 0.070 |
Why?
|
| Software | 1 | 1991 | 677 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 804 | 0.070 |
Why?
|
| Leukemia, B-Cell | 1 | 2005 | 26 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 323 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 352 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.060 |
Why?
|
| Albumins | 1 | 2024 | 88 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2024 | 122 | 0.050 |
Why?
|
| Regenerative Medicine | 1 | 2023 | 30 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 267 | 0.050 |
Why?
|
| Industry | 1 | 2003 | 29 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 278 | 0.050 |
Why?
|
| Quality Control | 1 | 2003 | 119 | 0.050 |
Why?
|
| Biotechnology | 1 | 2003 | 55 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 132 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2023 | 262 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2023 | 161 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 4707 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2023 | 216 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 401 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 288 | 0.050 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 58 | 0.050 |
Why?
|
| Biological Products | 1 | 2003 | 113 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 325 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2024 | 2306 | 0.050 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 14 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 190 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 57 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 3270 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1167 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 1672 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 491 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5050 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 594 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 430 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2020 | 322 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 109 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 1089 | 0.040 |
Why?
|
| United States | 2 | 2024 | 10632 | 0.040 |
Why?
|
| Prognosis | 2 | 2021 | 4508 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 77 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 496 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 35 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 80 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 114 | 0.040 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 58 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 59 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2017 | 98 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1239 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1998 | 609 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 17486 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2044 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 237 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 157 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 41 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 812 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 103 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 113 | 0.030 |
Why?
|
| Infant | 3 | 2024 | 12347 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 224 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1681 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 519 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 73 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6034 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 511 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 123 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 87 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 803 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 650 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1004 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 257 | 0.020 |
Why?
|
| Microcomputers | 1 | 1991 | 10 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 1991 | 30 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 33714 | 0.020 |
Why?
|
| Drug Incompatibility | 1 | 1991 | 1 | 0.020 |
Why?
|
| Ondansetron | 1 | 1991 | 10 | 0.020 |
Why?
|
| Drug Compounding | 1 | 1991 | 34 | 0.020 |
Why?
|
| Solutions | 1 | 1991 | 65 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1991 | 45 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2014 | 280 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2024 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2005 | 473 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1991 | 165 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1991 | 236 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1991 | 424 | 0.020 |
Why?
|
| Transduction, Genetic | 2 | 2002 | 288 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 6211 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1991 | 533 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 1062 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 752 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 676 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1565 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2397 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 43 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2005 | 16 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 77 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2005 | 82 | 0.020 |
Why?
|
| Immune System | 1 | 2005 | 87 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2005 | 233 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2005 | 313 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1781 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 16022 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 420 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3529 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2005 | 368 | 0.010 |
Why?
|
| Texas | 1 | 1991 | 3560 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2002 | 33 | 0.010 |
Why?
|
| Panniculitis | 1 | 2002 | 19 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 126 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 102 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 229 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 187 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 462 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 319 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 505 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 770 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1998 | 183 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 252 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 193 | 0.010 |
Why?
|